A rising cancer prevention target of RSK2 in human skin cancer

Frontiers in Oncology

Volumn 3 AUG, Issue , 2013, Pages

  Arul, Narayanasamy ^a   Cho, Yong Yeon ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Carcinogenesis; Chemoprevention; RSK2; RSK2 inhibitors; Skin cancer

Indexed keywords

1, 4 DIAMINO 1, 4 BIS (2 AMINOPHENYLTHIO) 2, 3 DICYANOBUTADIENE; 1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; 3 PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE; ACTIVATING TRANSCRIPTION FACTOR 1; CASPASE 8; COLLAGEN TYPE 1; CYCLIN DEPENDENT KINASE 3; DESMIN; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; EPIDERMAL GROWTH FACTOR RECEPTOR; ERIODICTYOL; KAEMPFEROL; LAMIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MYC PROTEIN; OSTEOCALCIN; OSTEOCLAST DIFFERENTIATION FACTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BCL 2; PROTEIN KINASE C; PROTEIN P53; RAF PROTEIN; RAS PROTEIN; S6 KINASE; SYNAPTOPHYSIN; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR NFAT3; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIMENTIN;

APOPTOSIS; ARTICLE; CANCER PREVENTION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL SURVIVAL; CELL TRANSFORMATION; DRUG TARGETING; GENE EXPRESSION; HUMAN; NERVE CELL PLASTICITY; NONHUMAN; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; SKIN CANCER; TUMOR GROWTH; UBIQUITINATION; WESTERN BLOTTING; X RAY CRYSTALLOGRAPHY;

EID: 84891081971     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00201     Document Type: Article

References (86)

1. Bowden GT. Prevention of non-melanoma skin cancer by targeting ultraviolet-B-light signalling. Nat Rev Cancer (2004) 4:23-35. doi:10.1038/nrc1253
2. American Cancer Society. Cancer Facts & Figures 2013, in: Annual Report. (Atlanta, GA: American Cancer society) (2013). Available from: http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/documents/document/acspc-036845.pdf
3. Remedy Health Media. Basal Cell Carcinoma, in: Health Encyclopedia. (New York, NY: Health Central) (2013). Available from: http://www.healthcentral.com/encyclopedia/408/199.html
4. MedlinePlus. Basal Cell Carcinoma, in: Encyclopedia. (Bethesda, MD: U.S. National Library of Medicine) (2011). Available from: http://www.nlm.nih.gov/medlineplus/ency/article/000824.htm
5. Wong CS, Strange RC, Lear JT. Basal cell carcinoma. BMJ (2003) 327:794-8. doi:10.1136/bmj.327.7418.794
6. BC Cancer Agency. Epidemiology of Skin Cancer [Online]. (2013). Available from: http://www.bccancer.bc.ca/HPI/CE/skincancer/skincancercourses/readings/preventionreadings/Epidemiology.htm
7. Jerant AF, Johnson JT, Sheridan CD, Caffrey TJ. Early detection and treatment of skin cancer. Am Fam Physician (2000) 62:357-68.
8. Bode AM, Dong Z. Mitogen-activated protein kinase activation in UV-induced signal transduction. Sci STKE (2003) 2003:RE2. doi:10.1126/stke.2003.167.re2
9. Jones SW, Erikson E, Blenis J, Maller JL, Erikson RL. A Xenopus ribosomal protein S6 kinase has two apparent kinase domains that are each similar to distinct protein kinases. Proc Natl Acad Sci U S A (1988) 85:3377-81. doi:10.1073/pnas.85.10.3377
10. Alcorta DA, Crews CM, Sweet LJ, Bankston L, Jones SW, Erikson RL. Sequence and expression of chicken and mouse risk: homologs of Xenopus laevis ribosomal S6 kinase. Mol Cell Biol (1989) 9:3850-9.
11. Moller DE, Xia CH, Tang W, Zhu AX, Jakubowski M. Human rsk isoforms: cloning and characterization of tissue-specific expression. Am J Physiol (1994) 266:C351-9.
12. Zhang Y, Cho YY, Petersen BL, Bode AM, Zhu F, Dong Z. Ataxia telangiectasia mutated proteins, MAPKs, and RSK2 are involved in the phosphorylation of STAT3. J Biol Chem (2003) 278:12650-9. doi:10.1074/jbc.M210368200
13. Cho YY, He Z, Zhang Y, Choi HS, Zhu F, Choi BY, et al. The p53 protein is a novel substrate of ribosomal S6 kinase 2 and a critical intermediary for ribosomal S6 kinase 2 and histone H3 interaction. Cancer Res (2005) 65:3596-603. doi:10.1158/0008-5472.CAN-04-3935
14. Choi HS, Choi BY, Cho YY, Mizuno H, Kang BS, Bode AM, et al. Phosphorylation of histone H3 at serine 10 is indispensable for neoplastic cell transformation. Cancer Res (2005) 65:5818-27. doi:10.1158/0008-5472.CAN-05-0197
15. David JP, Mehic D, Bakiri L, Schilling AF, Mandic V, Priemel M, et al. Essential role of RSK2 in c-Fos-dependent osteosarcoma development. J Clin Invest (2005) 115:664-72. doi:10.1172/JCI200522877
16. Cho YY, Yao K, Kim HG, Kang BS, Zheng D, Bode AM, et al. Ribosomal S6 kinase 2 is a key regulator in tumor promoter induced cell transformation. Cancer Res (2007) 67:8104-12. doi:10.1158/0008-5472.CAN-06-4668
17. Cho YY, Yao K, Pugliese A, Malakhova ML, Bode AM, Dong Z. A regulatory mechanism for RSK2 NH(2)-terminal kinase activity. Cancer Res (2009) 69:4398-406. doi:10.1158/0008-5472.CAN-08-4959
18. Liu K, Cho YY, Yao K, Nadas J, Kim DJ, Cho EJ, et al. Eriodictyol inhibits RSK2-ATF1 signaling and suppresses EGF-induced neoplastic cell transformation. J Biol Chem (2011) 286:2057-66. doi:10.1074/jbc.M110.147306
19. Cho YY, Lee MH, Lee CJ, Yao K, Lee HS, Bode AM, et al. RSK2 as a key regulator in human skin cancer. Carcinogenesis (2012) 33:2529-37. doi:10.1093/carcin/bgs271
20. Hendrich B, Bickmore W. Human diseases with underlying defects in chromatin structure and modification. Hum Mol Genet (2001) 10:2233-42. doi:10.1093/hmg/10.20.2233
21. Erikson E, Maller JL. A protein kinase from Xenopus eggs specific for ribosomal protein S6. Proc Natl Acad Sci U S A (1985) 82:742-6. doi:10.1073/pnas.82.3.742
22. Erikson RL. Structure, expression, and regulation of protein kinases involved in the phosphorylation of ribosomal protein S6. J Biol Chem (1991) 266:6007-10.
23. Blenis J. Signal transduction via the MAP kinases: proceed at your own RSK. Proc Natl Acad Sci U S A (1993) 90:5889-92. doi:10.1073/pnas.90.13.5889
24. Schierup MH, Hein J. Consequences of recombination on traditional phylogenetic analysis. Genetics (2000) 156:879-91.
25. Malakhova M, Tereshko V, Lee SY, Yao K, Cho YY, Bode A, et al. Structural basis for activation of the autoinhibitory C-terminal kinase domain of p90 RSK2. Nat Struct Mol Biol (2008) 15:112-3. doi:10.1038/nsmb1347
26. Malakhova M, Kurinov I, Liu K, Zheng D, D'angelo I, Shim JH, et al. Structural diversity of the active N-terminal kinase domain of p90 ribosomal S6 kinase 2. PLoS ONE (2009) 4:e8044. doi:10.1371/journal.pone.0008044
27. Smith KJ, Carter PS, Bridges A, Horrocks P, Lewis C, Pettman G, et al. The structure of MSK1 reveals a novel autoinhibitory conformation for a dual kinase protein. Structure (2004) 12:1067-77. doi:10.1016/j.str.2004.02.040
28. Ikuta M, Kornienko M, Byrne N, Reid JC, Mizuarai S, Kotani H, et al. Crystal structures of the N-terminal kinase domain of human RSK1 bound to three different ligands: implications for the design of RSK1 specific inhibitors. Protein Sci (2007) 16:2626-35. doi:10.1110/ps.073123707
29. Dalby KN, Morrice N, Caudwell FB, Avruch J, Cohen P. Identification of regulatory phosphorylation sites in mitogen-activated protein kinase (MAPK)-activated protein kinase-1a/p90rsk that are inducible by MAPK. J Biol Chem (1998) 273:1496-505. doi:10.1074/jbc.273.3.1496
30. Sibilia M, Wagner EF. Strain-dependent epithelial defects in mice lacking the EGF receptor. Science (1995) 269:234-8. doi:10.1126/science.7618085
31. Threadgill DW, Dlugosz AA, Hansen LA, Tennenbaum T, Lichti U, Yee D, et al. Targeted disruption of mouse EGF receptor: effect of genetic background on mutant phenotype. Science (1995) 269:230-4. doi:10.1126/science.7618084
32. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull (1991) 47:87-98.
33. Hunter T, Karin M. The regulation of transcription by phosphorylation. Cell (1992) 70:375-87. doi:10.1016/0092-8674(92)90162-6
34. Angel P, Imagawa M, Chiu R, Stein B, Imbra RJ, Rahmsdorf HJ, et al. Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor. Cell (1987) 49:729-39. doi:10.1016/0092-8674(87)90611-8
35. Sachsenmaier C, Radler-Pohl A, Zinck R, Nordheim A, Herrlich P, Rahmsdorf HJ. Involvement of growth factor receptors in the mammalian UVC response. Cell (1994) 78:963-72. doi:10.1016/0092-8674(94)90272-0
36. Ben-Ari ET, Bernstein LR, Colburn NH. Differential c-jun expression in response to tumor promoters in JB6 cells sensitive or resistant to neoplastic transformation. Mol Carcinog (1992) 5:62-74. doi:10.1002/mc.2940050111
37. Dong Z, Birrer MJ, Watts RG, Matrisian LM, Colburn NH. Blocking of tumor promoter-induced AP-1 activity inhibits induced transformation in JB6 mouse epidermal cells. Proc Natl Acad Sci U S A (1994) 91:609-13. doi:10.1073/pnas.91.2.609
38. Frodin M, Gammeltoft S. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol (1999) 151:65-77. doi:10.1016/S0303-7207(99)00061-1
39. Kornhauser JM, Greenberg ME. A kinase to remember: dual roles for MAP kinase in long-term memory. Neuron (1997) 18:839-42. doi:10.1016/S0896-6273(00)80322-0
40. Zhao Y, Bjorbaek C, Moller DE. Regulation and interaction of pp90(rsk) isoforms with mitogen-activated protein kinases. J Biol Chem (1996) 271:29773-9. doi:10.1074/jbc.271.47.29773
41. Smith JA, Poteet-Smith CE, Malarkey K, Sturgill TW. Identification of an extracellular signal-regulated kinase (ERK) docking site in ribosomal S6 kinase, a sequence critical for activation by ERK in vivo. J Biol Chem (1999) 274:2893-8. doi:10.1074/jbc.274.5.2893
42. Jensen CJ, Buch MB, Krag TO, Hemmings BA, Gammeltoft S, Frodin M. 90-kDa ribosomal S6 kinase is phosphorylated and activated by 3-phosphoinositide-dependent protein kinase-1. J Biol Chem (1999) 274:27168-76. doi:10.1074/jbc.274.38.27168
43. Cho YY, Tang F, Yao K, Lu C, Zhu F, Zheng D, et al. Cyclin-dependent kinase-3-mediated c-Jun phosphorylation at Ser63 and Ser73 enhances cell transformation. Cancer Res (2009) 69:272-81. doi:10.1158/0008-5472.CAN-08-3125
44. Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer (2004) 4:937-47. doi:10.1038/nrc1503
45. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and-independent mechanisms. Science (1999) 286:1358-62. doi:10.1126/science.286.5443.1358
46. Kang S, Dong S, Gu TL, Guo A, Cohen MS, Lonial S, et al. FGFR3 activates RSK2 to mediate hematopoietic transformation through tyrosine phosphorylation of RSK2 and activation of the MEK/ERK pathway. Cancer Cell (2007) 12:201-14. doi:10.1016/j.ccr.2007.08.003
47. Chen W, Tang Q, Gonzales MS, Bowden GT. Role of p38 MAP kinases and ERK in mediating ultraviolet-B induced cyclooxygenase-2 gene expression in human keratinocytes. Oncogene (2001) 20:3921-6. doi:10.1038/sj.onc.1204530
48. Kabuyama Y, Hamaya M, Homma Y. Wavelength specific activation of PI 3-kinase by UVB irradiation. FEBS Lett (1998) 441:297-301. doi:10.1016/S0014-5793(98)01565-8
49. El-Abaseri TB, Fuhrman J, Trempus C, Shendrik I, Tennant RW, Hansen LA. Chemoprevention of UV light-induced skin tumorigenesis by inhibition of the epidermal growth factor receptor. Cancer Res (2005) 65:3958-65. doi:10.1158/0008-5472.CAN-04-2204
50. El-Abaseri TB, Putta S, Hansen LA. Ultraviolet irradiation induces keratinocyte proliferation and epidermal hyperplasia through the activation of the epidermal growth factor receptor. Carcinogenesis (2006) 27:225-31. doi:10.1093/carcin/bgi220
51. Hauge C, Frodin M. RSK and MSK in MAP kinase signalling. J Cell Sci (2006) 119:3021-3. doi:10.1242/jcs.02950
52. Cross DA, Alessi DR, Cohen P, Andjelkovich M, Hemmings BA. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature (1995) 378:785-9. doi:10.1038/378785a0
53. Zhang F, Phiel CJ, Spece L, Gurvich N, Klein PS. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. Evidence for autoregulation of GSK-3. J Biol Chem (2003) 278:33067-77. doi:10.1074/jbc.M212635200
54. Frame S, Cohen P. GSK3 takes centre stage more than 20 years after its discovery. Biochem J (2001) 359:1-16. doi:10.1042/0264-6021:3590001
55. She QB, Ma WY, Zhong S, Dong Z. Activation of JNK1, RSK2, and MSK1 is involved in serine 112 phosphorylation of Bad by ultraviolet B radiation. J Biol Chem (2002) 277:24039-48. doi:10.1074/jbc.M109907200
56. Peng C, Cho YY, Zhu F, Zhang J, Wen W, Xu Y, et al. Phosphorylation of caspase-8 (Thr-263) by ribosomal S6 kinase 2 (RSK2) mediates caspase-8 ubiquitination and stability. J Biol Chem (2011) 286:6946-54. doi:10.1074/jbc.M110.172338
57. Yang X, Matsuda K, Bialek P, Jacquot S, Masuoka HC, Schinke T, et al. ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell (2004) 117:387-98. doi:10.1016/S0092-8674(04)00344-7
58. St-Arnaud R, Elchaarani B. Identification of additional dimerization partners of FIAT, the factor inhibiting ATF4-mediated transcription. Ann N Y Acad Sci (2007) 1116:208-15. doi:10.1196/annals.1402.028
59. Ameri K, Harris AL. Activating transcription factor 4. Int J Biochem Cell Biol (2008) 40:14-21. doi:10.1016/j.biocel.2007.01.020
60. Ku NO, Omary MB. Identification of the major physiologic phosphorylation site of human keratin 18: potential kinases and a role in filament reorganization. J Cell Biol (1994) 127:161-71. doi:10.1083/jcb.127.1.161
61. Sassone-Corsi P, Mizzen CA, Cheung P, Crosio C, Monaco L, Jacquot S, et al. Requirement of Rsk-2 for epidermal growth factor-activated phosphorylation of histone H3. Science (1999) 285:886-91. doi:10.1126/science.285.5429.886
62. Gurley LR, D'anna JA, Barham SS, Deaven LL, Tobey RA. Histone phosphorylation and chromatin structure during mitosis in Chinese hamster cells. Eur J Biochem (1978) 84:1-15. doi:10.1111/j.1432-1033.1978.tb12135.x
63. Lau AT, Lee SY, Xu YM, Zheng D, Cho YY, Zhu F, et al. Phosphorylation of histone H2B serine 32 is linked to cell transformation. J Biol Chem (2011) 286:26628-37. doi:10.1074/jbc.M110.215590
64. Bhatt RR, Ferrell JE Jr. Cloning and characterization of Xenopus Rsk2, the predominant p90 Rsk isozyme in oocytes and eggs. J Biol Chem (2000) 275:32983-90. doi:10.1074/jbc.M006386200
65. Jacobs MD, Harrison SC. Structure of an IkappaBalpha/NF-kappaB complex. Cell (1998) 95:749-58. doi:10.1016/S0092-8674(00)81698-0
66. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol (2000) 18:621-63. doi:10.1146/annurev.immunol.18.1.621
67. Micheau O, Lens S, Gaide O, Alevizopoulos K, Tschopp J. NF-kappaB signals induce the expression of c-FLIP. Mol Cell Biol (2001) 21:5299-305. doi:10.1128/MCB.21.16.5299-5305.2001
68. Yang P, McKay BS, Allen JB, Jaffe GJ. Effect of NF-kappa B inhibition on TNF-alpha-induced apoptosis in human RPE cells. Invest Ophthalmol Vis Sci (2004) 45:2438-46. doi:10.1167/iovs.03-0805
69. Nakajima A, Komazawa-Sakon S, Takekawa M, Sasazuki T, Yeh WC, Yagita H, et al. An antiapoptotic protein, c-FLIPL, directly binds to MKK7 and inhibits the JNK pathway. EMBO J (2006) 25:5549-59. doi:10.1038/sj.emboj.7601423
70. Peng C, Cho YY, Zhu F, Xu YM, Wen W, Ma WY, et al. RSK2 mediates NF-{kappa}B activity through the phosphorylation of IkappaBalpha in the TNF-R1 pathway. FASEB J (2010) 24:3490-9. doi:10.1096/fj.09-151290
71. Tiainen M, Ylikorkala A, Makela TP. Growth suppression by Lkb1 is mediated by a G(1) cell cycle arrest. Proc Natl Acad Sci U S A (1999) 96:9248-51. doi:10.1073/pnas.96.16.9248
72. Cho YY, Yao K, Bode AM, Bergen HR 3rd, Madden BJ, Oh SM, et al. RSK2 mediates muscle cell differentiation through regulation of NFAT3. J Biol Chem (2007) 282:8380-92. doi:10.1074/jbc.M611322200
73. Zhu F, Zykova TA, Peng C, Zhang J, Cho YY, Zheng D, et al. Phosphorylation of H2AX at Ser139 and a new phosphorylation site Ser16 by RSK2 decreases H2AX ubiquitination and inhibits cell transformation. Cancer Res (2011) 71:393-403. doi:10.1158/0008-5472.CAN-10-2012
74. Sapkota GP, Kieloch A, Lizcano JM, Lain S, Arthur JS, Williams MR, et al. Phosphorylation of the protein kinase mutated in Peutz-Jeghers cancer syndrome, LKB1/STK11, at Ser431 by p90(RSK) and cAMP-dependent protein kinase, but not its farnesylation at Cys(433), is essential for LKB1 to suppress cell growth. J Biol Chem (2001) 276:19469-82. doi:10.1074/jbc.M009953200
75. Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem (1998) 273:5858-68. doi:10.1074/jbc.273.10.5858
76. Clark DE, Poteet-Smith CE, Smith JA, Lannigan DA. Rsk2 allosterically activates estrogen receptor alpha by docking to the hormone-binding domain. EMBO J (2001) 20:3484-94. doi:10.1093/emboj/20.13.3484
77. Clark DE, Errington TM, Smith JA, Frierson HF Jr, Weber MJ, Lannigan DA. The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Cancer Res (2005) 65:3108-16.
78. Smith JA, Poteet-Smith CE, Xu Y, Errington TM, Hecht SM, Lannigan DA. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res (2005) 65:1027-34.
79. Nguyen TL, Gussio R, Smith JA, Lannigan DA, Hecht SM, Scudiero DA, et al. Homology model of RSK2 N-terminal kinase domain, structure-based identification of novel RSK2 inhibitors, and preliminary common pharmacophore. Bioorg Med Chem (2006) 14:6097-105. doi:10.1016/j.bmc.2006.05.001
80. Macdonald IA, Bokkenheuser VD, Winter J, Mclernon AM, Mosbach EH. Degradation of steroids in the human gut. J Lipid Res (1983) 24:675-700.
81. Selma MV, Espin JC, Tomas-Barberan FA. Interaction between phenolics and gut microbiota: role in human health. J Agric Food Chem (2009) 57:6485-501. doi:10.1021/jf902107d
82. Bokkenheuser VD, Shackleton CH, Winter J. Hydrolysis of dietary flavonoid glycosides by strains of intestinal Bacteroides from humans. Biochem J (1987) 248:953-6.
83. Utepbergenov D, Derewenda U, Olekhnovich N, Szukalska G, Banerjee B, Hilinski MK, et al. Insights into the inhibition of the p90 ribosomal S6 kinase (RSK) by the flavonol glycoside SL0101 from the 1.5 A crystal structure of the N-terminal domain of RSK2 with bound inhibitor. Biochemistry (2012) 51:6499-510. doi:10.1021/bi300620c
84. Sapkota GP, Cummings L, Newell FS, Armstrong C, Bain J, Frodin M, et al. BI-D1870 is a specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochem J (2007) 401:29-38. doi:10.1042/BJ20061088
85. Cohen MS, Zhang C, Shokat KM, Taunton J. Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science (2005) 308:1318-21. doi:10.1126/science1108367
86. Lawrie AM, Noble ME, Tunnah P, Brown NR, Johnson LN, Endicott JA. Protein kinase inhibition by staurosporine revealed in details of the molecular interaction with CDK2. Nat Struct Biol (1997) 4:796-801. doi:10.1038/nsb1097-796